You have been chosen to receive this valuable information.
 
A SPECIAL
ANNOUNCEMENT FROM:
   PE Logo  
ALT-EM-Header.jpg
ALT-EM-OneOff-TrialSim.jpg

How to Use Realistic Covariates with New Trial Simulator to Optimize Dosing

9 out of 10 drugs in development fail to make it to market, costing pharmaceutical companies billions every year. One reason for trial failures is suboptimal trial design.

Trial simulation is a powerful and efficient approach to computer-assisted trial design. Certara’s new Trial Simulator v2.3 balances ease-of-use with robust tools for defining study design attributes. You can conduct statistical and sensitivity analysis and create graphical summaries with R and ggplot2 to plan effective trials for every phase of clinical drug testing. While it delivers an intuitive user interface to help new users learn trial simulation quickly, Trial Simulator can also be applied to the most complex trial situations.

In our upcoming webinar, see Trial Simulator in action as Dr. Edward Nehus of Cincinnati Children’s Hospital and Dr. Mark Lovern, VP of Integrated Drug Development at Certara, evaluate target attainment of meropenem and degrees of fluid overload in children receiving continuous renal replacement therapy.

Date: November 27, 2018
Time: 11:00 am EDT

Button-Register-Blue.png
 
youtubetwitterfacebooklinkedin
About Certara

Certara is a leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes. Certara’s solutions, which span the drug development and patient care lifecycle, help increase the probability of regulatory and commercial success by using the most scientifically advanced modeling and simulation technologies and regulatory strategies. Its clients include hundreds of global biopharmaceutical companies, leading academic institutions and key regulatory agencies.

Corporate Headquarters: 100 Overlook Center, Suite 101, Princeton, NJ 08540 USA

© Copyright Certara 2018   |   For more information visit www.certara.com.
curved bottom shadow
If you no longer wish to receive these emails you may unsubscribe at any time.
 
Message above is a paid advertisement. Content is provided by the sponsor. You received this email because you are a customer of Pharmaceutical Executive, a UBM publication. You are on the mailing list as %%emailaddress%%.